Organization
Catalan Institute of Oncology-Hospitalet
10 abstracts
Abstract
First-line pembrolizumab for lung cancer in a Spanish real-world study.Org: Hospital Universitario Dr. Balmis de Alicante ISABIAL, Hospital Universitario La Coruña, Oncology Pharmacy Department, Catalan Institute of Oncology-Hospitalet, Hospital Universitario de Asturias,
Abstract
HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer brain metastases.Org: Yale University, Catalan Institute of Oncology-Hospitalet, Hospital Duran i Reynals, IDIBELL Medical Oncology,
Abstract
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitario 12 de Octubre, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO), Institut Catala d'Oncologia Badalona,
Abstract
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Exploring HER2-low disease: Does it impact breast cancer survival?Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology-Hospitalet, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona,
Abstract
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.Org: Hospital Universitario Puerta de Hierro-Majadahonda, Hospital Universitario A Coruña, Son Espases University Hospital, Hospital Regional Carlos Haya, Catalan Institute of Oncology-Hospitalet,
Abstract
Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer.Org: Invitrocue Europe AG, Invitrocue Hong Kong Ltd, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Technical University of Munich (TUM), Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China,
Abstract
Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.Org: Catalan Institute of Oncology-Hospitalet, Hospital Josep Trueta, IDIBGi, Hospital Germans Trias i Pujol, IGTP (Health Research Institute Germans Trias i Pujol),
Abstract
Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).Org: Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto Investigacion Sanitaria Puerta de Hierro-Segovia de Arana, Fundación para la Investigación Biomédica Hospital Universitario Puerta de Hierro, C/ Joaquín Rodrigo, 1, 28222 Majadahonda,
Abstract
Clinical features of long-term survivors with advanced high-grade serous ovarian cancer.Org: Medical Oncology Group, Catalan Institute of Oncology and Girona Biomedical Research Institute, Medical School University of Girona, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology-Hospitalet,